Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US panel to look at patient communication vehicles

This article was originally published in Scrip

Executive Summary

TheUS FDA's risk communication advisory committee will meet on February 26th-27th to discuss the different types of prescription drug information currently available to patients in the form of medication guides, patient package inserts and consumer medical information (CMI) leaflets. The review will include results of a survey on the percentage of patients who receive "useful" written information, in the form of CMI, with their prescriptions.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts